AgomAb Therapeutics NV (AGMB) Cash & Equivalents (2023 - 2026)
Agomab Therapeutics (AGMB) reported Cash & Equivalents of $257.57 million for Q2 2026.
Powered by 
Analysis
AgomAb Therapeutics NV (AGMB) Cash & Equivalents (2023 - 2026) Analysis & Trends
At the end of FY2025, Agomab Therapeutics posted Cash & Equivalents of $97.64 million, down 47.4% from FY2024.
- By year, Cash & Equivalents came in at $185.58 million in FY2024 (+40.2%) and $132.4 million in FY2023.
Peer Set
Peer Comparison
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 253.10 Mn |
| Dec 31, 2025 | 101.52 Mn |
| Dec 31, 2024 | 178.42 Mn |
| Dec 31, 2023 | 135.48 Mn |
API Access
AgomAb Therapeutics NV Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=AGMB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "AGMB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=AGMB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();